

*You are cordially invited to participate in a continuing education (CE) meeting:*

# **Case Studies in the Proactive Management of Indolent and Mantle Cell Lymphomas**

**Tuesday, May 18, 2010**

**6:00pm – Registration**

**6:30pm – Presentation**

Jack's Oyster House

42 State Street

Albany, NY 12207

(518) 465-8854

*Dinner will be served*

Please RSVP to Laura Daigle at (518) 694-7110 or [laura.daigle@acphs.edu](mailto:laura.daigle@acphs.edu)

## **Speaker**

**David Frame, PharmD**

University of Michigan

Ann Arbor, Michigan

**This CE activity provides 1.0 contact hour for nurses and pharmacists.**

**In accordance with PhRMA guidelines, guests are not permitted to attend.  
This program is intended for invited, registered healthcare professionals.**

This activity is jointly sponsored by  
Medical Learning Institute, Inc. and Avid Education Partners, LLC



Medical Learning Institute, Inc.  
LEADERS IN MEDICAL ACCREDITATION



Supported by an educational grant from  
Millennium Pharmaceuticals, Inc. and Cephalon Oncology.



## STATEMENT OF NEED

The American Cancer Society (ACS) estimated that in 2009 there would be 65,900 new cases of non-Hodgkin's lymphoma (NHL) and 19,500 deaths due to NHL, making NHL one of the leading causes of cancer and cancer-related deaths in the United States. NHL has been classified into two types, indolent and aggressive. Two types are difficult to treat: indolent and mantle cell. Indolent lymphoma makes up 70% of NHL and generally presents with slowly progressive disease and painless peripheral lymphadenopathy. Characterized by a relatively slow rate of growth, indolent lymphomas have a low potential for cure with currently available treatments. The majority of indolent lymphoma patients are diagnosed with advanced-stage disease and the median survival is approximately 8-10 years.

Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma that comprises 6% of NHLs. Patients with MCL typically present in an advanced stage with widespread lymphadenopathy, involvement of the bone marrow, and a predilection for gastrointestinal infiltration. Although the majority of MCL patients are able to achieve response, relapse almost always occurs. Currently, MCL has no standard therapy at diagnosis or relapse and no curative options exist. The aggressive clinical course of MCL has resulted in a median overall survival of 3-4 years with fewer than 15% of patients alive at 5 years. Treatments of indolent lymphoma and MCL are areas of ongoing research and promising results with combination therapy and novel agents were recently presented at the 2008 American Society of Hematology (ASH) meeting in San Francisco.

Due to the high incidence rate of indolent lymphomas, community practice oncology nurses and pharmacists need to understand patient management issues associated with the "watch-and-wait" treatment strategy for asymptomatic patients as well as available treatment options for symptomatic disease. Community practice oncology healthcare professionals (HCPs) may not be familiar with MCL due to the relatively few cases diagnosed per year. However, the aggressive nature of MCL makes appropriate management more intense and treatment more difficult than that of indolent lymphomas. Clinical trials in indolent lymphoma and MCL are generally conducted in academic institutions and it becomes challenging for oncology nurses and pharmacists not directly involved in the trials to keep abreast of the latest data. Through discussion of case studies, from diagnosis through recurrence, oncology HCPs will have a better understanding of newer treatments and research, as well as their potential impact of managing lymphoma patients.

## TARGET AUDIENCE

This activity is designed for oncology nurses and pharmacists interested in learning more about indolent and mantle cell lymphomas and the results of the latest research that promise to improve clinical outcomes.

## LEARNING OBJECTIVES

At the end of each program participants will be able to:

- Describe the typical clinical presentation of indolent and mantle cell lymphomas
- Discuss the pharmacology of treatment regimens
- Identify the side effects seen with therapies
- Enact interventions for symptom management of frequently occurring side effects of bio-/chemotherapy

## ACCREDITATION

Medical Learning Institute, Inc. (MLI) is an approved provider of continuing nursing education by the California Board of Registered Nursing, Provider Number 15106, for 1.0 contact hour.



MLI is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This CE activity provides 1.0 contact hour. The universal program number for this activity is 0468-999-09-044-L01-P.

## FACULTY DISCLOSURE

It is the policy of MLI and Avid Education Partners, LLC (AEP) to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial product(s) to be discussed during their presentation(s). Presenters will inform participants of any off-label discussions. The associates of MLI and AEP have no financial relationships to disclose.